Fund+ successfully led a EUR 21.3 million Series B capital round of Minoryx Therapeutics

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, has completed a Series B capital round of EUR 21.3 million. The proceeds will enable Minoryx to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication.
The capital round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors. Argo acted as legal counsel to Fund+ and its co-investors SFPI-FPIM, S.R.I.W. and Sambrinvest.